Our XGBoost model, supported by SHAP analysis empowers clinicians with interpretable insights and defined risk thresholds and could facilitate informed decision-making and patient-centric care.
No takes yet. Share an insight, caveat, or question.
Schindele et al. (2025) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: